Citations

Clear

4610 citation(s) found for "Lu, Brian".

Paraneoplastic Neurologic Syndromes Associated with Testicular Germ Cell Tumors: Clinical and Serological Characteristics (S38.005)
Harahsheh, Ehab , Hammami, M Bakri , Costello, Brian A. , Cheville, John C. , Ζεκερίδου, Αναστασία , McKeon, Andrew, Bakri, Hammami M , Gupta, Pranjal , McKeon, Andrew , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206707 Get It

Vagus Nerve Stimulation for Epilepsy During Pregnancy (P7-1.012)
Vu, Anhmai , Razaq, Aisha Abdul, Tatum, William O. , Drees, Cornelia , Szymanski, Linda M. , Britton, Jeffrey W. , Drees, Cornelia , Coon, Elizabeth A. , Lundstrom, Brian N. , Smith, Kelsey M.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205667 Get It

Hypoperfusion Index Ratio is Associated with Early Neurological Deficit Severity and Decline after Mechanical Thrombectomy in Large Vessel Occlusion Ischemic Stroke (P2-5.004)
Miller, Małgorzata , Wideman, Brian, Khan, Muhib , Henninger, Nils

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206386 Get It

Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Chonde, Meshe , Cooper, Howard A., Ginder, Curtis , Kontos, Michael C. , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Park, Jeong‐Gun , Pierce, Matthew , Pisani, Barbara , Teuteberg, Jeffrey J. , Katz, Jason N. , Chonde, Meshe D , Miller, P Elliott , Newby, L Kristin , O'Brien, Connor G , Park, Jeong-Gun , Pierce, Matthew J , Pisani, Barbara A , Potter, Brian J , Teuteberg, Jeffrey J , Katz, Jason N , van Diepen, Sean , Morrow, David A , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ginder, Curtis , Jentzer, Jacob C. , Shah, Kevin S , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Circulation: Heart Failure | April 8, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.124.011736 | PMID 38587438 Get It

BACKGROUND: Associations of early changes in vasoactive support with cardiogenic shock (CS) mortality remain incompletely defined. METHODS: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units. Patients admitted with CS (2018–2023) had vasoactive dosing assessed at 4 and 24 hours from cardiac intensive care unit admission and quantified by the vasoactive-inotropic score (VIS). Prognostic associations of VIS at both time points, as well as change in VIS from 4 to 24 hours, were examined. Interaction testing was performed based on mechanical circulatory support status. RESULTS: Among 3665 patients, 82% had a change in VIS <10, with 7% and 11% having a ≥10-point increase and decrease from 4 to 24 hours, respectively. The 4 and 24-hour VIS were each associated with cardiac intensive care unit mortality (13%–45% and 11%–73% for VIS <10 to ≥40, respectively; P trend <0.0001 for each). Stratifying by the 4-hour VIS, changes in VIS from 4 to 24 hours had a graded association with mortality, ranging from a 2- to >4-fold difference in mortality comparing those with a ≥10-point increase to ≥10-point decrease in VIS ( P trend <0.0001). The change in VIS alone provided good discrimination of cardiac intensive care unit mortality (C-statistic, 0.72 [95% CI, 0.70–0.75]) and improved discrimination of the 24-hour Sequential Organ Failure Assessment score (0.72 [95% CI, 0.69–0.74] to 0.76 [95% CI, 0.74–0.78]) and the clinician-assessed Society for Cardiovascular Angiography and Interventions shock stage (0.72 [95% CI, 0.70–0.74] to 0.77 [95% CI, 0.75–0.79]). Although present in both groups, the mortality risk associated with VIS was attenuated in patients managed with versus without mechanical circulatory support (odds ratio per 10-point higher 24-hour VIS, 1.36 [95% CI, 1.23–1.49] versus 1.84 [95% CI, 1.69–2.01]; P interaction <0.0001). CONCLUSIONS: Early changes in the magnitude of vasoactive support in CS are associated with a gradient of risk for mortality. These data suggest that early VIS trajectory may improve CS prognostication, with the potential to be leveraged for clinical decision-making and research applications in CS.
The role of occipital condyle and atlas anomalies on occipital cervical fusion outcomes in Chiari malformation type I with syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Koueik, Joyce , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Kaufman, Bruce A., Keating, Robert F., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , Martin, Jonathan E. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jackson, Eric M. , Jallo, George I. , Johnston, James M. , Khan, Nickalus R. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D. , Ahmed, Raheel

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 6, 2024 | Volume: 34 | Issue: 1 | Pages: 66-74

10.3171/2024.1.peds23229 | PMID 38579359 Get It

OBJECTIVE Congenital anomalies of the atlanto-occipital articulation may be present in patients with Chiari malformation type I (CM-I). However, it is unclear how these anomalies affect the biomechanical stability of the craniovertebral junction (CVJ) and whether they are associated with an increased incidence of occipitocervical fusion (OCF) following posterior fossa decompression (PFD). The objective of this study was to determine the prevalence of condylar hypoplasia and atlas anomalies in children with CM-I and syringomyelia. The authors also investigated the predictive contribution of these anomalies to the occurrence of OCF following PFD (PFD+OCF). METHODS The authors analyzed the prevalence of condylar hypoplasia and atlas arch anomalies for patients in the Park-Reeves Syringomyelia Research Consortium database who underwent PFD+OCF. Condylar hypoplasia was defined by an atlanto-occipital joint axis angle (AOJAA) ≥ 130°. Atlas assimilation and arch anomalies were identified on presurgical radiographic imaging. This PFD+OCF cohort was compared with a control cohort of patients who underwent PFD alone. The control group was matched to the PFD+OCF cohort according to age, sex, and duration of symptoms at a 2:1 ratio. RESULTS Clinical features and radiographic atlanto-occipital joint parameters were compared between 19 patients in the PFD+OCF cohort and 38 patients in the PFD-only cohort. Demographic data were not significantly different between cohorts (p > 0.05). The mean AOJAA was significantly higher in the PFD+OCF group than in the PFD group (144° ± 12° vs 127° ± 6°, p < 0.0001). In the PFD+OCF group, atlas assimilation and atlas arch anomalies were identified in 10 (53%) and 5 (26%) patients, respectively. These anomalies were absent (n = 0) in the PFD group (p < 0.001). Multivariate regression analysis identified the following 3 CVJ radiographic variables that were predictive of OCF occurrence after PFD: AOJAA ≥ 130° (p = 0.01), clivoaxial angle < 125° (p = 0.02), and occipital condyle–C2 sagittal vertical alignment (C–C2SVA) ≥ 5 mm (p = 0.01). A predictive model based on these 3 factors accurately predicted OCF following PFD (C-statistic 0.95). CONCLUSIONS The authors’ results indicate that the occipital condyle–atlas joint complex might affect the biomechanical integrity of the CVJ in children with CM-I and syringomyelia. They describe the role of the AOJAA metric as an independent predictive factor for occurrence of OCF following PFD. Preoperative identification of these skeletal abnormalities may be used to guide surgical planning and treatment of patients with complex CM-I and coexistent osseous pathology.
Centralized Multipatient Dashboards' Impact on Intensive Care Unit Clinician Performance and Satisfaction: A Systematic Review
Strechen, Inna , Barwise, Amelia , García-Méndez, Juan , Rovati, Lucrezia , Pickering, Brian W. , Diedrich, Daniel A. , Herasevich, Svetlana , Diedrich, Daniel, Barwise, Amelia K , Garcia-Mendez, Juan, Herasevich, Vitaly

Mayo Clinic

Applied Clinical Informatics | April 4, 2024 | Volume: 15 | Issue: 03 | Pages: 414-427

10.1055/a-2299-7643 | PMID 38574763 Get It

Abstract Background Intensive care unit (ICU) clinicians encounter frequent challenges with managing vast amounts of fragmented data while caring for multiple critically ill patients simultaneously. This may lead to increased provider cognitive load that may jeopardize patient safety. Objectives This systematic review assesses the impact of centralized multipatient dashboards on ICU clinician performance, perceptions regarding the use of these tools, and patient outcomes. Methods A literature search was conducted on February 9, 2023, using the EBSCO CINAHL, Cochrane Central Register of Controlled Trials, Embase, IEEE Xplore, MEDLINE, Scopus, and Web of Science Core Collection databases. Eligible studies that included ICU clinicians as participants and tested the effect of dashboards designed for use by multiple users to manage multiple patients on user performance and/or satisfaction compared with the standard practice. We narratively synthesized eligible studies following the SWiM (Synthesis Without Meta-analysis) guidelines. Studies were grouped based on dashboard type and outcomes assessed. Results The search yielded a total of 2,407 studies. Five studies met inclusion criteria and were included. Among these, three studies evaluated interactive displays in the ICU, one study assessed two dashboards in the pediatric ICU (PICU), and one study examined centralized monitor in the PICU. Most studies reported several positive outcomes, including reductions in data gathering time before rounds, a decrease in misrepresentations during multidisciplinary rounds, improved daily documentation compliance, faster decision-making, and user satisfaction. One study did not report any significant association. Conclusion The multipatient dashboards were associated with improved ICU clinician performance and were positively perceived in most of the included studies. The risk of bias was high, and the certainty of evidence was very low, due to inconsistencies, imprecision, indirectness in the outcome measure, and methodological limitations. Designing and evaluating multipatient tools using robust research methodologies is an important focus for future research.
Industry payments to American Society of Hematology Clinical Practice Guideline authors
Jacobs, Jeremy W. , Booth, Garrett S. , Adkins, Brian D. , Martin, Amarilis , Lundberg, George D., Glover, Raeshun T, Khan, Shazia S , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura D. , Silver, Julie K. , Woo, Jennifer S.

Mayo Clinic

Blood Advances | April 3, 2024 | Volume: 8 | Issue: 13 | Pages: 3549-3552

10.1182/bloodadvances.2023012527 | PMID 38569136 Get It

Recurrence morbidity of olfactory neuroblastoma
Melder, Katie , Mace, Jess C. , Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Fernandez‐Miranda, Juan C. , Fung, Nicholas K., Gardner, Paul A. , Hwang, Peter H. , Ji, Keven Seung Yong , Kalyvas, Aristotelis , Kong, Keonho A., Patel, Chirag , Patel, Zara M. , Celda, María Peris, Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Sanusi, Olabisi , Choby, Garret , Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2024 | Volume: 14 | Issue: 9 | Pages: 1435-1445

10.1002/alr.23351 | PMID 38567900 Get It

AbstractBackgroundWith modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease‐specific survival (DSS), and further recurrence.MethodsA retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time‐to‐event analyses.ResultsA final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5‐year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.ConclusionsRecurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma
Necela, Brian M. , Bahr, Deborah, Vivekanandhan, Sneha , Shreeder, Barath , Knutson, Keith L.

Mayo Clinic

No container title available | April 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4004491/v1 | PMID 38645250 Get It

Abstract In this study, we tested a novel approach of “repurposing” a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2 (the animal homolog to HER2/neu). This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7.16.4). The c-erb-B2-expressing melanoma was designated B16/neu. 7.16.4 produced statistically significant in vivo anti-tumor responses against B16/neu. This effect was mediated by NK-cell antibody-dependent cell-mediated cytotoxicity. To further model human melanoma (which expresses <5% HER2/neu), our c-erb-B2 encoding lentivirus was used to inoculate naïve (wild-type) B16 tumors in vivo, resulting in successful c-erb-B2 expression. When combined with 7.16.4, anti-tumor responses were again demonstrated where approximately 40% of mice treated with c-erb-B2 lentivirus and 7.16.4 achieved complete clinical response and long-term survival. For the first time, we demonstrated a novel strategy to repurpose c-erb-B2 as a neoantigen target for melanoma. Our findings are particularly significant in the contemporary setting where newer anti-HER2/neu antibody-drug candidates have shown increased efficacy.